Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 5/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30539815 | 1.00 | TLR8 (0.39) | TLR8TLR7NLRP3ADORA3ADORA2A | |
| SCHEMBL30539848 | 0.90 | NLRP3 (0.43) | TLR8TLR7NLRP3ADORA3ADORA2A | |
| SCHEMBL23037608 | 0.90 | NLRP3 (0.43) | TLR8TLR7NLRP3ADORA3ADORA2A | |
| SCHEMBL27194822 | 0.89 | TLR8 (0.42) | TLR8TLR7NLRP3ADORA3ADORA2A | |
| SCHEMBL29314604 | 0.89 | TLR8 (0.43) | TLR8TLR7NLRP3ADORA3ADORA2A | |
| SCHEMBL29314605 | 0.85 | TLR8 (0.46) | TLR8TLR7NLRP3ADORA3ADORA2A | |
| SCHEMBL29320192 | 0.85 | TLR7 (0.39) | TLR8TLR7NLRP3DHFR | |
| SCHEMBL23037589 | 0.84 | TLR8 (0.38) | TLR8TLR7NLRP3 | |
| SCHEMBL30539846 | 0.84 | TLR8 (0.38) | TLR8TLR7NLRP3 | |
| SCHEMBL29315550 | 0.84 | TLR7 (0.34) | TLR8TLR7NLRP3ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| US-12037344-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4353235-A2 | NLRP3 MODULATORS | Innate Tumor Immunity, Inc. (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-112521387-B | NLRP3 modulators | 先天肿瘤免疫公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-112521387-A | NLRP3 modulators | 先天肿瘤免疫公司 | 2021-03-19 | — | — | CN | disclosed |
| EP-3784670-A1 | NLRP3 MODULATORS | Innate Tumor Immunity, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| CN-112074516-A | NLRP3 modulators | 先天肿瘤免疫公司 | 2020-12-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037344-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | TLR8 210/4885TLR7 236/4885NLRP3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.